中枢神经系统生物标记市场 - 按生物标记类型、应用、最终用途 - 全球预测，2024 年 - 2032 年

由于生物标记研究的进步及其在药物发现和临床试验中的采用，2024 年至 2032 年间，全球中枢神经系统生物标记市场将以 8.1% 的复合年增长率增长。这些生物标记为疾病机制、治疗反应和患者分层提供了重要的见解，从而促进了标靶治疗的开发。随着製药公司越来越依赖生物标记来简化药物开发流程并改善治疗结果，对神经系统疾病的创新生物标记解决方案的需求将会上升，有助于市场扩张。

例如，2024 年 3 月，Alamar Biosciences 推出了超高灵敏度 NULISAseq(TM) CNS 疾病 Panel 120 和 NULISAqpcr(TM) PTau-217 检测。 NULISAseq CNS 疾病 Panel 120 可对神经系统疾病进行多重蛋白质分析，而 NULISAqpcr pTau-217 检测（ALZpath 抗体）则专注于失智症研究。

中枢神经系统生物标记产业根据生物标誌物类型、应用、最终用途和地区进行分类。

由于对可深入了解神经系统疾病治疗效果的生物标记的需求，功效生物标记细分市场到 2032 年将大幅成长。功效生物标记提供有关治疗反应和疾病进展的重要资料，有助于个人化医疗方法。随着焦点转向精准医学，製药公司和临床医生依靠这些生物标记来开发标靶疗法。由于其在治疗优化中的重要作用，功效生物标记部分将保持在中枢神经系统生物标记市场的主导地位。

药物发现和开发领域的中枢神经系统生物标记市场规模将在2024 年和2032 年期间出现显着激增。关键作用。这些标记物提供了对疾病机制、治疗反应和患者分层的深入了解，这对于开发有效的疗法至关重要。製药公司依靠生物标记来简化临床试验并优化药物开发流程。随着对精准医学的日益关注，药物发现和开发领域将站在最前沿，推动神经系统治疗的进步。

受该地区不断发展的医疗基础设施和不断上升的神经系统疾病发病率的推动，亚太地区中枢神经系统生物标记行业将在 2024 年至 2032 年间实现显着的复合年增长率。中国和印度等国家人口基数庞大，医疗保健投资不断增加，是这一成长的主要贡献者。此外，亚太地区生物标记研究和诊断的进步也促进了市场扩张。以改善神经系统疾病管理为重点，亚太地区将成为中枢神经系统生物标记市场的重要贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 神经系统疾病盛行率上升
    • 生物标记发现技术不断进步
    • 不断增加的政府措施和政策
    • 增加中枢神经系统生物标记的使用
  • 产业陷阱与挑战
    • 与中枢神经系统生物标记测试和诊断相关的高成本
    • 严格的监管场景
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按生物标记类型，2018 年 - 2032 年

• 主要趋势
• 安全生物标记
• 功效生物标记
• 验证生物标记
• 其他生物标誌物

第 6 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 疾病诊断
• 药物发现与开发
• 个人化药物
• 其他应用

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院和诊所
• 诊断实验室
• 学术及研究机构
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• bioMerieux
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• G-Biosciences
• Illumina, Inc.
• Merck KGaA
• Myriad Genetics, Inc.
• Novartis AG
• PerkinElmer Inc.
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

Global Central Nervous System Biomarkers Market will grow at an 8.1% CAGR between 2024 and 2032, owing to advancements in biomarker research and their adoption in drug discovery and clinical trials. These biomarkers offer crucial insights into disease mechanisms, treatment responses, and patient stratification, enhancing the development of targeted therapies. As pharmaceutical companies increasingly rely on biomarkers to streamline drug development processes and improve treatment outcomes, the demand for innovative biomarker solutions for neurological disorders will rise, contributing to market expansion.

For instance, in March 2024, Alamar Biosciences unveiled the Ultra-High Sensitivity NULISAseq(TM) CNS Disease Panel 120 and NULISAqpcr(TM) PTau-217 Assays. The NULISAseq CNS Disease Panel 120 enables multiplexed protein analysis for neurological disorders, while the NULISAqpcr pTau-217 Assay (ALZpath antibody) focuses on dementia research.

The central nervous system biomarkers industry is classified based on biomarker type, application, end-use, and region.

The efficacy biomarker segment will witness a considerable rise by 2032 due to the demand for biomarkers that provide insights into treatment effectiveness for neurological disorders. Efficacy biomarkers offer crucial data on therapeutic responses and disease progression, aiding in personalized medicine approaches. As the focus shifts towards precision medicine, pharmaceutical companies and clinicians rely on these biomarkers to develop targeted therapies. With their vital role in treatment optimization, the efficacy biomarker segment will maintain dominance in the central nervous system biomarkers market.

The central nervous system biomarkers market size from the drug discovery and development segment will see a notable surge during 2024 and 2032. As researchers strive for innovative treatments for neurological disorders, biomarkers play a pivotal role in drug discovery. These markers provide insights into disease mechanisms, treatment responses, and patient stratification crucial for developing effective therapies. Pharmaceutical companies rely on biomarkers to streamline clinical trials and optimize drug development processes. With an increasing focus on precision medicine, the drug discovery and development segment will stand at the forefront, driving advancements in neurological treatments.

Asia Pacific central nervous system biomarkers industry will capture a noteworthy CAGR between 2024 and 2032, driven by the region's growing healthcare infrastructure and rising incidence of neurological disorders. Countries like China and India are key contributors to this growth, with their large population base and increasing investment in healthcare. Additionally, advancements in biomarker research and diagnostics in APAC bolster market expansion. With a focus on improving neurological disease management, Asia Pacific will emerge as a substantial contributor to the central nervous system biomarkers market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of neurological disorders
    • 3.2.1.2 Increasing advancements in biomarker discovery technologies
    • 3.2.1.3 Rising government initiatives and policies
    • 3.2.1.4 Increasing use of CNS biomarkers
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with CNS biomarker tests and diagnostics
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Biomarker Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Safety biomarker
• 5.3 Efficacy biomarker
• 5.4 Validation biomarker
• 5.5 Other biomarkers

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Disease diagnosis
• 6.3 Drug discovery and development
• 6.4 Personalized medicines
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals & clinics
• 7.3 Diagnostic laboratories
• 7.4 Academic & research institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 bioMerieux
• 9.2 Bio-Rad Laboratories, Inc.
• 9.3 F. Hoffmann-La Roche Ltd
• 9.4 G-Biosciences
• 9.5 Illumina, Inc.
• 9.6 Merck KGaA
• 9.7 Myriad Genetics, Inc.
• 9.8 Novartis AG
• 9.9 PerkinElmer Inc.
• 9.10 Siemens Healthineers AG
• 9.11 Sysmex Corporation
• 9.12 Thermo Fisher Scientific Inc.